SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications.

MLA

Lyon, Robert P., et al. “SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications.” Molecular Cancer Therapeutics, vol. 22, no. 12, Dec. 2023, pp. 1444–53. EBSCOhost, https://doi.org/10.1158/1535-7163.MCT-22-0817.

APA

Lyon, R. P., Jonas, M., Frantz, C., Trueblood, E. S., Yumul, R., Westendorf, L., Hale, C. J., Stilwell, J. L., Yeddula, N., Snead, K. M., Kumar, V., Patilea-Vrana, G. I., Klussman, K., & Ryan, M. C. (2023). SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications. Molecular Cancer Therapeutics, 22(12), 1444–1453. https://doi.org/10.1158/1535-7163.MCT-22-0817

Chicago

Lyon, Robert P, Mechthild Jonas, Christopher Frantz, Esther S Trueblood, Roma Yumul, Lori Westendorf, Christopher J Hale, et al. 2023. “SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications.” Molecular Cancer Therapeutics 22 (12): 1444–53. doi:10.1158/1535-7163.MCT-22-0817.